Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways
Authors:
Open Access
- 20 May 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113140
Abstract
No abstract availableKeywords
Funding Information
- Yunnan Provincial Science and Technology Department
- Major Science and Technology Projects in Yunnan Province (2018IA060)
This publication has 35 references indexed in Scilit:
- LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorptionNature Medicine, 2016
- Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κBInternational Journal of Molecular Sciences, 2015
- The Role of Chinese Medicine in the Treatment of Chronic Diseases in ChinaPlanta Medica, 2011
- Disorders of Bone RemodelingAnnual Review of Pathology: Mechanisms of Disease, 2011
- Physiology of Bone2009
- αvβ3and macrophage colony‐stimulating factor: partners in osteoclast biologyImmunological Reviews, 2005
- Osteoclast differentiation and activationNature, 2003
- Control of osteoblast function and regulation of bone massNature, 2003
- Phosphatidylinositol 3‐kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survivalJournal of Cellular Biochemistry, 2003
- RANK-L and RANK: T Cells, Bone Loss, and Mammalian EvolutionAnnual Review of Immunology, 2002